DP8 Stock Chart & Stats
€3.22
-€0.06(-2.68%)
At close: 4:00 PM EST
€3.22
-€0.06(-2.68%)
Day’s Range― - ―
52-Week Range€1.81 - €8.95
Previous CloseN/A
Volume0.00
Average Volume (3M)15.00
Market Cap
€33.10M
Enterprise Value€27.33M
Total Cash (Recent Filing)€12.92M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Aug 17, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.27
Shares Outstanding13,526,233
10 Day Avg. Volume0
30 Day Avg. Volume15
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.84Price Target Upside454.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.31
Revenue Forecast (FY)€196.05K
Bulls Say, Bears Say
Bulls Say
Patent ProtectionA U.S. notice of allowance extending neflamapimod protection into 2042 creates a durable exclusivity window for DLB indications. Long patent life strengthens bargaining power with partners, supports long-term ROI on development spend, and helps secure future licensing or commercialization value.
Clinical Data Driving Phase 3 PlanRobust biomarker, imaging and PK/PD analyses refined dose-exposure targets and identified subgroups with benefit, permitting a regulator-aligned Phase 3 strategy. This reduces execution risk by clarifying endpoints, dosing, and target population, improving the odds of a successful pivotal program.
Low Financial LeverageA zero-debt balance sheet lowers near-term solvency risk and avoids interest burdens, giving management flexibility to raise equity or structure partnerships without immediate refinancing pressure. This is a durable structural strength when funding future clinical milestones.
Bears Say
High Cash BurnSustained negative operating cash flow of roughly -$27.6M TTM indicates the company must repeatedly access external capital to fund trials. Persistent cash burn raises dilution and execution risk, constraining the pace and scale of development absent firm partnership or large financings.
Minimal, Declining RevenueRevenue has fallen sharply to negligible levels, showing no commercial footing. With essentially no product sales, the firm remains fully dependent on financing and grants, limiting internal ability to fund R&D and making long-term sustainability contingent on successful development or external deals.
Eroding Equity BaseMaterial decline in shareholders' equity reflects accumulated losses and asset drawdown, shrinking the balance-sheet buffer against setbacks. This reduces financial flexibility, may hamper future non-dilutive financing, and heightens vulnerability if clinical or regulatory hurdles delay value-creating milestones.
CervoMed News
DP8 FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was €1.81 and its highest was €8.95 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is €33.10M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is Aug 17, 2026 which is in 26 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on May 18, 2026. The company reported -€0.739 earnings per share for the quarter, missing the consensus estimate of -€0.676 by -€0.064.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.69.
How many shares outstanding does CervoMed have?
CervoMed has 13,526,233 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -€0.739 in its last earnings report, missing expectations of -€0.676. Following the earnings report the stock price went down -9.15%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in DE:DP8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CervoMed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€17.84 (454.06% Upside)
€17.84 (454.06% Upside)
Insider Transactions
Bought Shares
Worth €2.6M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-60.82%
Trailing 12-Months
Company Description
CervoMed
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
DP8 Stock 12 Month Forecast
Average Price Target
€17.84
▲(454.06% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―